Nintedanib

Extended indication	Mesothelioom
Therapeutic value	No judgement
Total cost	15,475,000.00

Product

Active substance	Nintedanib
Domain	Oncology and Hematology
Main indication	Mesothelioma
Extended indication	Mesothelioom
Proprietary name	Vargatef
Manufacturer	Boehringer Ingelheim
Route of administration	Oral
Therapeutical formulation	Capsule
Budgetting framework	Intermural (MSZ)

Registration

Registration route	Centralised (EMA)
Expected Registration	August 2019
Orphan drug	No
Additional remarks	Dit is een indicatie-uitbreiding.

Therapeutic value

Therapeutic value	No judgement
Duration of treatment	Not found
Frequency of administration	2 times a day
Dosage per administration	200 mg
Additional remarks	In combinatie met pemetrexed en cisplatin

Expected patient volume per year

Patient volume	< 619 Market share is generally not included unless otherwise stated.
References	NKR
Additional remarks	NKR 2016: 619 diagnoses pleuramesothelioom

Patient volume

< 619

Market share is generally not included unless otherwise stated.

References

NKR

Additional remarks

NKR 2016: 619 diagnoses pleuramesothelioom

Expected cost per patient per year

Cost	20,000.00 - 30,000.00
References	Fabrikant
Additional remarks	100mg=€1.683 p/m; 150mg=€2.524p/m

Potential total cost per year

Total cost	15,475,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Total cost

15,475,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension	Yes
Indication extensions	Er lopen meerdere PhIII studies.

Other information

There is currently no futher information available.